Randomized, comparative study of interferon β-1a treatment regimens in MSHillel Panitch, Brian G. Weinshenker, Douglas S. Goodin et al.|Neurology|2002Cited by 633
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D. Mikol, Bernard M.J. Uitdehaag, Frederik Barkhof et al.|The Lancet Neurology|2008Cited by 484
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.Jack H. Simon, Jerry S. Wolinsky, David K.B. Li et al.|PubMed|2006Cited by 287
The utility of MRI in suspected MS [RETIRED]Elliot M. Frohman, W. H. Stuart, Douglas S. Goodin et al.|Neurology|2003Cited by 190
Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trialHillel Panitch, Brian G. Weinshenker, Paul O’Connor et al.|Journal of the Neurological Sciences|2005Cited by 98